A study on adverse events following immunisation among COVID-19 vaccine recipients at a tertiary care hospital in Kashmir valley
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20230035Keywords:
Immunisation, Adverse events, COVID, Vaccination, Side effectsAbstract
Background: Adverse events following immunization (AEFI) is an event of unexpected medical emergency occurring after vaccination without any causal association with vaccination. It can be any unintended, abnormal laboratory finding or anything. The present study was conducted to evaluate the incidence and severity of AEFI associated with the COVID-19 vaccines.
Methods: All the beneficiaries who had received two doses of Covishield and Covaxin vaccine from SKIMS Soura and provided consent were included in this prospective study. Each beneficiary was contacted telephonically. A self- designed questionnaire was used to interview them. The beneficiaries were contacted twice. The data was entered into and analysed using SPSS version 20.
Results: A total of 267 participants (52.3%) reported at least one of the AEFI following Covaxin vaccine. It was found that participants with AEFIs following the first dose had more chances to develop them following its second dose and this difference was found to be statistically significant (OR=6.8, p=0.0001). A total of 670 participants (38.0%) reported at least one of the AEFI following Covishield vaccine. The incidence of AEFIs was more after the first dose (31.6%) than that of the second dose (6.4%) and this difference was found to be statistically significant (p<0.0001).
Conclusions: Most of the AEFI are minor and can be managed symptomatically. Therefore, these AEFIs should not be a hurdle for vaccination.
References
World Health Organization. WHO coronavirus (COVID-19) dashboard. Available at: https://covid19.who.int. Updated 2022. Accessed on Sept 01, 2022.
Xiao Y, Torok ME. Taking the right measures to control COVID-19. Lancet Infect Dis. 2020;20(5):523-4.
Ministry of Health and Family Welfare. Government of India announces a Liberalised and Accelerated Phase 3 Strategy of Covid-19 Vaccination from 1st May. Available at: https://www.narendramodi.in/ government-of-india-announces-a-liberalised-andaccelerated-phase-3-strategy-of-covid-19-vaccination-from-1st-may-5550504. Accessed on 9 July 2021.
26k Adverse Events, 488 Deaths Reported in India During Covid Vaccination Drive: Data. Available at: https://www.freepressjournal.in/india/india-reports-26-thousand-adverse-events-488-deaths-during-covid-vaccination-drive. Accessed on 9 July 2021.
Wagner AL, Shotwell AR, Boulton ML, Carlson BF, Mathew JL. Demographics of Vaccine Hesitancy in Chandigarh, India. Front Med. 2021;1062.
Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. Vaccine. 2020;38(40):6194-8.
Parida SP, Sahu DP, Singh AK. Adverse events following immunization of COVID‐19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol. 2022;94:2453-9.
Kamal M, Omirah MA, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021;75:e137469.
Menni C, Klaser K, May A. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21:939-49.
